The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular profile of hepatocellular carcinoma (HCC) in older (OA) versus younger adults (YA) receiving tyrosine kinase inhibitors: Does age matter?
 
Jay Parekh
No Relationships to Disclose
 
Nishant Gandhi
Employment - Caris Life Sciences
 
Neil Newman
No Relationships to Disclose
 
James Denno
No Relationships to Disclose
 
Joanne Xiu
Employment - Caris Life Sciences
 
Matthew Oberley
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Sanjay Goel
Stock and Other Ownership Interests - Johnson and Johnson; Merck; Moderna Therapeutics
Honoraria - GlaxoSmithKline
Research Funding - Amgen (Inst); Deciphera (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); Xilio Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364
 
Andreas Seeber
No Relationships to Disclose
 
Gilberto Lopes
Stock and Other Ownership Interests - Biomab; CDR-Life; Lucence Diagnostics; Morphometrix; Xilis
Honoraria - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Dr. Reddy's Laboratories; Janssen; Merck; Rigel
Consulting or Advisory Role - AstraZeneca; Coherus Biosciences; Dr. Reddy's Laboratories; Mirati Therapeutics; Pfizer; Regeneron
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); E.R. Squibb Sons, LLC; EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst); Xilis
Travel, Accommodations, Expenses - AstraZeneca; BeiGene; Boehringer Ingelheim; Celgene; Coherus Biosciences; Dr. Reddy's Laboratories; E.R. Squibb Sons, LLC; Ipsen; Janssen; Merck; Pfizer; Pharmacyclics; Seagen; Seagen
 
Sukeshi Arora
Honoraria - Targeted Oncology
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Exelixis; Seagen
Speakers' Bureau - AstraZeneca; Bristol-Meyers Squibb; Seagen
Travel, Accommodations, Expenses - DAVA Oncology